Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

NEXT STORY
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
PREV STORY
BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors

author_avatar
NASDAQ Market News

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

author_avatar
NASDAQ Market News

OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland

author_avatar
NASDAQ Market News